DOI:
10.1055/s-00000025
Hormone and Metabolic Research
LinksClose Window
References
Rizvi NA, Mazieres J, Planchard D. et al.
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial.
Lancet Oncol 2015;
16: 257-265
We do not assume any responsibility for the contents of the web pages of other providers.